cpi-rsv-f
Vaccineexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 20, 2022 (NCT05281263)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Respiratory syncytial virusUnclear
Respiratory syncytial virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05655182 | Phase 1/Phase 2 (Phase 2) | Jan 23, 2023 | Blue Lake Biotechnology Inc., University of Cincinnati |
| NCT05281263 | Phase 1 | Jul 20, 2022 | Blue Lake Biotechnology Inc., University of Cincinnati |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Blue Lake Biotechnology Inc. | For profit | 2 | 2 | 2 | 2022 |
| University of Cincinnati | Academic/Hospital | 2 | 0 | 2 | 2022 |
2 organizations
Page 1 / 1